FOLH1 and prostate cancer: Triggered by the introduction of 68Ga-PSMA-11 PSMA PET in 2012 (1) for the diagnosis and staging of prostate cancer (2,3), PSMA-targeted diagnostic imaging and subsequently developed therapeutic approaches (4–6) have become valuable new tools in the clinical management of prostate cancer (7).